Norgine Strengthens Rare Disease Portfolio with Acquisition of Theravia
Deal News | Apr 15, 2025 | EIN
Norgine, a specialty pharmaceutical company, has announced the acquisition of Theravia, an international pharmaceutical company focused on treatments for rare diseases, from Merieux Equity Partners. This acquisition aligns with Norgine's strategy to become a leading player in the rare and specialty pharmaceuticals market in Europe. Theravia specializes in medications for rare hematology and hepatology conditions, offering products like SIKLOS for sickle cell disease and ORPHACOL for genetic bile production disorders. Norgine CEO Janneke van der Kamp emphasized the growth potential and expansion of their rare disease portfolio, complementing existing core products such as PEDMARQSI and mavorixafor. The acquisition is pending customary regulatory approvals.
Sectors
- Pharmaceuticals
- Private Equity
- Healthcare Investment
Geography
- Europe – The article is significantly focused on the European market as both Norgine and Theravia, and the selling private equity firm are based in Europe, with a focus on expanding access to medicines in this region.
- France – Theravia's majority shareholder, Merieux Equity Partners, and Theravia itself are both based in France, playing a crucial role in the acquisition process.
- Australia and New Zealand – Norgine has operational interests and markets its products in Australia and New Zealand, as stated in their core market strategy.
Industry
- Pharmaceuticals – This industry involves companies that research, develop, produce, and market drugs or pharmaceuticals for medication. Both Norgine and Theravia operate within this sector, with a focus on rare disease medication.
- Private Equity – Private Equity involves firms or funds that invest directly in private companies. Merieux Equity Partners, the majority shareholder of Theravia, operates within this sector, indicating its role in the transaction.
- Healthcare Investment – This sector encompasses investments in healthcare companies that are developing life-saving and innovative medical treatments. Merieux Equity Partners' focus on healthcare investments places this acquisition within this category.
Financials
- N/A – The article does not disclose specific financial figures regarding the acquisition transaction.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Norgine | Acquiring Company | Company | Norgine is a specialty pharmaceutical and consumer healthcare company with over 550 million in annual revenues, focused on rare and specialty medicines. |
| Theravia | Target Company | Company | An international pharmaceutical company specializing in treatments for rare diseases, formed through the merger of Addmedica and CTRS. |
| Merieux Equity Partners | Selling Company | Company | A European healthcare-focused investment firm, serving as the majority shareholder of Theravia. |
| Janneke van der Kamp | Chief Executive Officer, Norgine | Person | Cited as highlighting the growth potential of Norgine's expanded rare disease portfolio through the acquisition of Theravia. |
| Franck Hamalian | Chief Executive Officer, Theravia | Person | Quoted underscoring the strategic benefits of the merger between Norgine and Theravia, emphasizing skill and geographical benefits. |